Time needed to dissolve gout urate deposits when uric acid is kept very low
Official title: Time Required to Dissolve Urate Deposits in Patients With Gout
Run by Assistance Publique - Hôpitaux de Paris · NCT06669000 · Data updated 2026-11-12
This project tests whether keeping blood uric acid under 40 mg/L in people with gout will dissolve joint urate deposits and how long that takes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | September 24, 2024 |
| Main results expected | September 24, 2032 |
| Study ends | September 24, 2032 |
| Registry record updated | February 19, 2026 |
| Trial ID | NCT06669000 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with gout by 2015 ACR/EULAR criteria, serum urate >60 mg/L, an ultrasound score ≥2/24, not currently on urate-lowering therapy, and able to be followed at the study center are ideal candidates.
✕Probably not a fit
People already taking urate-lowering therapy, those with uncontrolled severe illnesses, pregnant or breastfeeding women, or those without French national social security are unlikely to benefit from joining this cohort.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
ReViGore40 will enroll adults with newly diagnosed gout who are not yet on urate-lowering therapy and who have ultrasound evidence of urate deposits. All participants will start xanthine oxidase inhibitors or uricosurics as appropriate and have their serum urate titrated to a target below 40 mg/L. Ultrasound of feet and knees will be performed every six months and an ultrasound score (0–24) will be used to define complete dissolution as two consecutive scores of 0 six months apart. The study will also collect clinical, biological and genetic data, perform DECT in tophaceous patients, provide patients with home urate meters, and bank blood samples for omics and epigenetic analyses.
Why it matters
Potential benefit: If successful, the results could show that a strict urate target speeds reliable dissolution of crystals and helps guide treatment toward remission.
How similar studies have gone: Previous work shows lowering serum urate can dissolve crystals and induce remission, but prospectively measuring time to complete dissolution at a strict <40 mg/L target with regular ultrasound is relatively new.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age over 18 years * Gout according to the ACR/Eular 2015 criteria * SUA levels greater than 60 mg/L * US score (MTP1s, knees) ≥2/24 * Informed consent Dated and signed voluntarily Exclusion Criteria: * Ongoing urate lowering therapy * Severe and uncontrolled diseases such as cancer, cardiovascular or neurovegetative diseases * Pregnant or breast-feeding women * No affiliation to the French National Social Security System
Where it's running
-
APHP, Lariboisière Hospital, Rheumatology departement
Paris, France Recruiting
Study contacts
- Study coordinator: Pascal RICHETTE, PR
- Email: pascal.richette@aphp.fr
- Phone: 0149956314
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dotinurad in gout patients who can’t tolerate XOI or failed uricase treatment
This trial tests whether dotinurad can lower uric acid levels in adults with gout who can’t use certain standard medicines or have not benefited from uricase.
-
Orienting project on crystal deposits in gout, CPPD, and osteoarthritis
This project will follow adults with gout or CPPD and people with osteoarthritis to see if crystal deposits in joints and blood vessels change over time and relate to treatments or heart problems.
-
Remote monitoring for gout in primary care
This project will test a smartphone self-management app to help adults with gout and high urate levels manage their condition alongside GP follow-up.
-
Purified Cortrophin® Gel for treating acute gout flares at two dose levels
This study will try two single injections (40 U and 80 U) of Purified Cortrophin® Gel to see which dose better and more quickly reduces pain in adults having an acute gout flare.
-
IV PRX-115 at different dose schedules, with or without methotrexate, versus placebo for adults with gout
This trial will test whether IV PRX-115 given on different schedules, with or without low-dose methotrexate, can lower uric acid and be safe in adults whose gout is not controlled by standard urate-lowering drugs.
-
Dotinurad versus allopurinol for lowering uric acid in gout
This trial tests whether dotinurad lowers blood uric acid more than allopurinol in adults with gout.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.